BRTX · Insider Trading
BioRestorative Therapies, Inc. Common Stock (NV)
Every open-market purchase and sale reported by BRTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-20 | Lance Alstodt | President, CEO, COB | A | +15,625 | +$25.00K |
| 2025-10-20 | Francisco Silva | VP of Research and Development | A | +11,719 | +$18.75K |
| 2025-02-19 | David A Rosa | Director | A | +52,632 deriv. | — |
| 2025-02-19 | Lance Alstodt | President, CEO, COB | A | — | — |
| 2025-02-19 | Nickolay V. Kukekov | Director | A | +52,632 deriv. | — |
| 2025-02-19 | Robert Eugene Kristal | Chief Financial Officer | A | — | — |
| 2025-02-19 | Patrick F. Williams | Director | A | +52,632 deriv. | — |
| 2025-02-19 | Francisco Silva | VP of Research and Development | A | — | — |
| 2024-11-05 | Dale Broadrick | 10%+ Owner | Sell | −1,112 | −$1.76K |
| 2024-04-10 | Francisco Silva | VP of Research and Development | Buy | +8,308 | +$10.23K |
| 2024-03-20 | Lance Alstodt | President, CEO, COB | F | −17,633 | −$24.51K |
| 2024-03-20 | Francisco Silva | VP of Research and Development | F | −17,193 | −$23.90K |
| 2024-02-15 | Nickolay V. Kukekov | Director | A | +79,646 deriv. | — |
| 2024-02-15 | Robert Paccasassi | VP, QA and Reg Compliance | A | +219,298 deriv. | — |
| 2024-02-15 | Robert Eugene Kristal | Chief Financial Officer | A | — | — |
| 2024-02-15 | Patrick F. Williams | Director | A | +79,646 deriv. | — |
| 2024-02-15 | David A Rosa | Director | A | +79,646 deriv. | — |
| 2024-02-15 | Francisco Silva | VP of Research and Development | A | — | — |
| 2024-02-15 | Lance Alstodt | President, CEO, COB | A | — | — |
| 2024-02-12 | Dale Broadrick | 10%+ Owner | Buy | +160,000 | +$206.02K |
| 2024-02-09 | Dale Broadrick | 10%+ Owner | Buy | +120,000 | +$162.25K |
| 2023-12-05 | Dale Broadrick | 10%+ Owner | Sell | −250 | −$469 |
| 2023-12-01 | Dale Broadrick | 10%+ Owner | Sell | −278 | −$525 |
| 2023-09-18 | Lance Alstodt | President, CEO, COB | Buy | +2,200 | +$3.74K |
| 2023-09-18 | Dale Broadrick | 10%+ Owner | Buy | +20,000 | +$32.00K |
| 2023-09-14 | Dale Broadrick | 10%+ Owner | Buy | +2,500 | +$5.17K |
| 2023-09-13 | Lance Alstodt | President, CEO, COB | Buy | +800 | +$1.23K |
| 2023-09-06 | Lance Alstodt | President, CEO, COB | Buy | +2,887 | +$5.66K |
| 2023-08-31 | Francisco Silva | VP of Research and Development | Buy | +4,954 | +$11.00K |
| 2023-07-28 | Dale Broadrick | 10%+ Owner | Buy | +1,000 | +$2.80K |
| 2023-07-25 | Lance Alstodt | President, CEO, COB | Buy | +4,200 | +$10.25K |
| 2023-04-04 | Francisco Silva | VP of Research and Development | Buy | +747 | +$2.66K |
| 2023-03-22 | Lance Alstodt | President, CEO, COB | F | −6,729 | −$19.65K |
| 2023-03-22 | Francisco Silva | VP of Research and Development | F | −6,729 | −$19.65K |
| 2023-03-03 | Dale Broadrick | 10%+ Owner | Buy | +6,200 | +$17.70K |
| 2023-02-28 | Francisco Silva | VP of Research and Development | F | −374 | −$1.12K |
| 2023-02-27 | Lance Alstodt | President, CEO, COB | F | −374 | −$1.12K |
| 2023-02-17 | Robert Eugene Kristal | Chief Financial Officer | A | — | — |
| 2023-02-17 | Patrick F. Williams | Director | A | +32,028 deriv. | — |
| 2023-02-17 | David A Rosa | Director | A | +32,028 deriv. | — |
| 2023-02-17 | Robert Paccasassi | VP, QA and Reg Compliance | A | +88,968 deriv. | — |
| 2023-02-17 | Nickolay V. Kukekov | Director | A | +32,028 deriv. | — |
| 2023-02-17 | Lance Alstodt | President, CEO, COB | A | — | — |
| 2023-02-17 | Francisco Silva | VP of Research and Development | A | — | — |
| 2023-02-02 | Lance Alstodt | President, CEO, COB | Buy | +400 | +$1.24K |
| 2023-01-30 | Lance Alstodt | President, CEO, COB | Buy | +200 | +$602 |
| 2023-01-24 | Lance Alstodt | President, CEO, COB | Buy | +200 | +$627 |
| 2023-01-20 | Lance Alstodt | President, CEO, COB | Buy | +400 | +$1.24K |
| 2023-01-10 | Lance Alstodt | President, CEO, COB | Buy | +100 | +$308 |
| 2022-12-28 | Lance Alstodt | President, CEO, COB | Buy | +300 | +$903 |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Dale Broadrick | 10%+ Owner | 46,196 | $105.33K |
| Lance Alstodt | President, CEO, COB | 9,375 | $21.37K |
| Francisco Silva | VP of Research and Development | 9,176 | $20.92K |
| Robert Eugene Kristal | Chief Financial Officer | 400 | $912 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BRTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.